Company / R&D Expense
ORAGENICS INC R&D Expense History
FY2013-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$4.1M
FY2024
5-year range
$4.1M / $10.6M
FY2020-FY2024
Trend
-59.2%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $11M to $4M over the past 2 years.
Based on SEC 10-K filings.
$4M in FY2024 with a 10-year CAGR of +3.0%.
Declined from $11M to $4M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -27.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- +3.0%
Key checks
Key Insights
- 3-year CAGR of -27.0%, indicating a declining trend.
- In FY2024, r&d expense decreased 59.2% year-over-year.
- Peak r&d expense was recorded in FY2022.
- Lowest r&d expense in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -147.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $4.1M | -59.2% |
| FY2023 | $10.1M | -4.9% |
| FY2022 | $10.6M | +0.0% |
| FY2021 | $10.6M | +77.3% |
| FY2018 | $6.0M | +25.6% |
| FY2017 | $4.8M | -45.6% |
| FY2016 | $8.7M | +184.9% |
| FY2015 | $3.1M | +0.0% |
| FY2014 | $3.1M | -61.0% |
| FY2013 | $7.9M | +0.0% |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026